Dyadic International to Announce Second Quarter 2017 Financial Results and Host Conference Call on Thursday August 10, 2017
28 July 2017 - 6:30AM
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on further improving and applying its
proprietary C1 expression system to help speed up the development
and production of biologic vaccines and drugs at flexible
commercial scales, announced today that it will report its
financial results for the quarter ended June 30, 2017 after the
market close on Thursday, August 10, 2017 and that it will host a
conference call that day at 5:00 p.m. Eastern Time to discuss those
results.
In order to participate in the live session,
please use the following dial-in numbers five to ten minutes prior
to the start time:
Calling from the United States or Canada: 888-515-2235
Calling from other countries: +
719-325-2177
Confirmation Code: 9865737
A replay of the conference call will be
available on Dyadic’s website (www.dyadic.com) within 24 hours
after the live event.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical protein production
system based on the fungus Myceliopthora thermophila, nicknamed C1.
The C1 microorganism, which enables the development and large scale
manufacture of low cost proteins, has the potential to be further
developed into a safe and efficient expression system that may help
speed up the development, production and performance of biologic
vaccines and drugs at flexible commercial scales. Dyadic is
using the C1 technology and other technologies to conduct research,
development and commercial activities for the development and
manufacturing of human and animal vaccines, monoclonal antibodies,
biosimilars and/or biobetters, and other therapeutic proteins.
Dyadic pursues research and development collaborations, licensing
arrangements and other commercial opportunities with its partners
and collaborators to leverage the value and benefits of these
technologies in developing and manufacturing biopharmaceuticals
which these technologies help produce. In particular, as the aging
population grows in developed and undeveloped countries, Dyadic
believes the C1 technology may help bring biologic drugs to market
faster, in greater volumes, at lower cost, and with new properties
to drug developers and manufacturers and, hopefully, improve access
and cost to patients and the healthcare system, but most
importantly save lives.
Please visit Dyadic’s website at
www.dyadic.com for additional information, including details
regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of the federal securities laws. Forward-looking statements
involve risks, uncertainties and other factors that could cause
Dyadic’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Investors are urged to consider these factors carefully
in evaluating the forward-looking statements and are cautioned not
to place undue reliance on such forward-looking statements. Any
forward-looking statements speak only as of the date of this press
release and, except as required by law, Dyadic expressly disclaims
any intent or obligation to update or revise any forward-looking
statements to reflect actual results, any changes in expectations
or any change in events. Factors that could cause results to differ
materially include, but are not limited to: (1) general economic,
political and market conditions; (2) our ability to carry out and
implement our biopharmaceutical research and business plans and
strategic initiatives; (3) Dyadic’s ability to retain and attract
employees, consultants, directors and advisors; (4) our ability to
implement and successfully carry out Dyadic’s and third parties
research and development efforts; (5) our ability to obtain new
license and research agreements; (6) our ability to maintain our
existing access to, and/or expand access to third party contract
research organizations in order to carry out our research projects
for ourselves and third parties; (7) competitive pressures and
reliance on key customers and collaborators; and (8) other factors
discussed in Dyadic’s publicly available filings, including
information set forth under the caption “Risk Factors” in our
December 31, 2016 Annual Report filed with OTC Markets on March 24,
2017. New risks and uncertainties arise from time to time, and it
is impossible for us to predict these events or how they may affect
us.
Contact:
Dyadic International, Inc.
Thomas L. Dubinski
Chief Financial Officer
Phone: 561-743-8333
Email: tdubinski@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Apr 2024 to May 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From May 2023 to May 2024